Launch of ESMO Virtual Plenaries Brings Rapid Access to Ground-breaking Cancer Research
17.2.2021 15:00:00 EET | Business Wire | Press release
ESMO, the leading organisation for medical oncology, has launched an important new service for rapidly disseminating research to accelerate the transition of results into practice for the benefit of cancer patients.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210217005495/en/
(Graphic: ESMO)
“In a world that runs fast, timeliness in bringing research advances to patients is critical. The lessons that we have learnt from the COVID-19 pandemic have taught us that we need to be creative in sharing research results, and we certainly don’t have to wait for the two or three times in the year when major oncology congresses take place,” says Solange Peters, ESMO President.
ESMO Virtual Plenaries will combine concise presentations of new data, insightful discussion and audience Q&A in live, easy-to-access, 60-minute online sessions at convenient times across international time zones. They will remain available on OncologyPRO, ESMO’s online resource portal, for subsequent viewing.
Every month, latest, original scientific data will be presented from randomised phase III oncology trials or phase II trials which demonstrate remarkable therapeutic benefit, scientific insight or progress in an area of unmet need.
“By timely presentation of clinical and scientific data, ESMO Virtual Plenaries will be complementary to and enhance the value of conventional scientific congresses, whilst adhering to the principles of peer review, analysis and audience interaction,” says George Pentheroudakis, ESMO Chief Medical Officer.
A maximum of two abstracts will be accepted for presentation each month (except September and November when ESMO hosts major congresses). Abstracts will be original data from international investigators, selected by appropriate independent ESMO specialists. After presentation and discussion in ESMO Virtual Plenaries, abstracts will be published in Annals of Oncology and will be eligible for encore presentation at the next ESMO Congress.
The first ESMO Virtual Plenary is on Friday, 19 February, 1300 CET
Efficacy of everolimus in patients with HR+/HER2- high risk early-stage breast cancer
The ESMO Virtual Plenaries are freely available to all healthcare professionals working in Oncology. ESMO Members or anyone with an already existing free ESMO Account will be able to log in and watch using their existing ESMO Account.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210217005495/en/
Contact information
European Society for Medical Oncology
Press Office
+41 91 973 19 01
media@esmo.org
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BioLife to Showcase Oral Peptide Delivery Technology During London Life Sciences Week3.11.2026 17:03:00 EET | Press release
BioLife Products Limited today announced its participation in London Life Sciences Week, where it will highlight its patented oral peptide delivery technology and recent advances in its intellectual property portfolio. BioLife will present at the LSX Investival Showcase on Monday, November 16, 2026, from 3:15 to 3:30 p.m. GMT, at Old Billingsgate, London. The presentation will be led by Former US Ambassador James P. Cain, Strategic Advisor to the Chairman & Founder, alongside Ludivine Delattre, Business and Corporate Relations, and will highlight the scientific journey behind the technology and its potential applications. BioLife is focused on developing a novel approach to delivering peptide therapeutics orally. Built on over 35 years of pharmaceutical effervescence expertise and two decades of oral peptide research by founder and inventor Dr. Farid Bennis, the technology uses a dissolvable effervescent tablet to create a buffered solution that helps protect peptides during gastrointe
Sceye and SoftBank Corp. Sign Agreement for Fleet of Stratospheric Platforms Targeting Nationwide Coverage in Japan3.11.2026 17:00:00 EET | Press release
Sceye, a U.S. aerospace and material science company building High Altitude Platform Systems (HAPS) for stratospheric infrastructure, today announced a five-year Master Services Agreement (MSA) with SoftBank Corp. (TOKYO:9434, “SoftBank”) to manufacture, launch, and operate a fleet of Sceye’s HAPS over Japan with the aim of achieving nationwide coverage. This agreement advances the companies’ partnership from flight demonstrations toward full-scale stratospheric infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103391128/en/ Sceye and SoftBank Corp. Sign Agreement for Fleet of Stratospheric Platforms Targeting Nationwide Coverage in Japan Sceye’s HAPS will form a key pillar of SoftBank’s strategy for a Ubiquitous Network. The majority of Sceye’s initial fleet will provide mobile broadband throughout Japan, while a subset will also establish a Free Space Optical (FSO) network in the stratosphere. These deploym
SharkNinja Brings Its All-Star Neighbors and Fans Home for the Holidays3.11.2026 17:00:00 EET | Press release
SharkNinja, Inc. (NYSE: SN), a global product design and technology company, today unveiled the final spot in its first-ever SharkNinja holiday campaign, starring global brand ambassadors David Beckham, Tom Brady, Kevin Hart, and Aryna Sabalenka. The campaign, “There’s No Home Like a SharkNinja Home,” puts the ambassadors’ own fandom and love of Shark and Ninja products at the center of a holiday house-sitting assignment that gets a little out of hand and invites fans along for the fun. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103325477/en/ David Beckham, Tom Brady, Kevin Hart, and Aryna Sabalenka celebrate a shared love and fandom of Shark and Ninja products in SharkNinja’s first-ever holiday campaign, “There’s No Home Like a SharkNinja Home” Created by SharkNinja’s in-house Creative Labs team and produced by Studio 99, the holiday campaign builds on SharkNinja’s Neighbors series, which debuted in 2025 with Beckham
Andersen Consulting Enhances Transformation Capabilities with Bakia Consulting3.11.2026 16:30:00 EET | Press release
Andersen Consulting advances its business transformation capabilities through a Collaboration Agreement with Bakia Consulting, a firm specializing in finance function transformation. Headquartered in Paris with capabilities in Singapore and Hong Kong, Bakia Consulting has helped large corporations and financial institutions redesign their finance functions, addressing operating models, organizational structures, processes, and digital systems. The firm combines project management and change management, working alongside clients to develop solutions and sustain change. Bakia Consulting also advises on financial and non-financial management models, process optimization, and digital tools. “Finance functions are being asked to deliver better insight, operate more efficiently, and adapt to changing business needs, often at the same time,” said Romain Dubuisson, partner at Bakia Consulting. “We work closely with clients to develop solutions that reflect their operational realities, combinin
Organigram to Acquire Aurora and Establish a Global Cannabis Leader3.11.2026 16:16:00 EET | Press release
Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI) (“Organigram”) and Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) (“Aurora”) today announced that they have entered into an arrangement agreement (the “Arrangement Agreement”) pursuant to which Organigram will acquire all of the issued and outstanding common shares (the “Aurora Shares”) of Aurora at a price of C$7.80 per Aurora Common Share (the “Transaction”). The Transaction values Aurora at approximately C$561 million on a fully diluted equity value basis. The consideration represents a 93% premium to the unaffected closing share price of Aurora Shares on the TSX as of August 10, 2026, the last full trading day of Aurora prior to the announcement by Curaleaf Holdings, Inc. (“Curaleaf”) of its intention to launch a hostile takeover bid for Aurora (the “Unaffected Price”), and a 21% premium relative to the current bid value of the Curaleaf hostile offer3 (the “Hostile Bid”) as most recently amended on October 6, 2026, which was unanimousl
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom